Cardiovascular Systems (FRA:R7Y1) ROCE % : -10.46% (As of Dec. 2022)

View and export this data going back to 2012. Start your Free Trial

What is Cardiovascular Systems ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cardiovascular Systems's annualized ROCE % for the quarter that ended in Dec. 2022 was -10.46%.

Cardiovascular Systems ROCE % Historical Data

The historical data trend for Cardiovascular Systems's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiovascular Systems ROCE % Chart

Cardiovascular Systems Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

ROCE %

Get a 7-Day Free Trial

2.19

0.96

-10.64

-3.73

-12.86

Cardiovascular Systems Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
ROCE %	Get a 7-Day Free Trial															-12.09	-13.25	-13.45	-15.18	-10.46

Cardiovascular Systems ROCE % Calculation

Cardiovascular Systems's annualized ROCE % for the fiscal year that ended in Jun. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2022 )		(A: Jun. 2021 )		(A: Jun. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2022 )		(A: Jun. 2021 )		(A: Jun. 2022 )
	=	-33.1	/	( ( (292.631 - 45.36)	+	(305.252 - 37.796) )	/ 2 )
	=	-33.1	/	( (247.271	+	267.456)	/ 2 )
	=	-33.1	/	257.3635
	=	-12.86 %

Cardiovascular Systems's ROCE % of for the quarter that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2022 )		(Q: Sep. 2022 )		(Q: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2022 )		(Q: Sep. 2022 )		(Q: Dec. 2022 )
	=	-28.076	/	( ( (315.158 - 37.527)	+	(294.062 - 34.702) )	/ 2 )
	=	-28.076	/	( ( 277.631	+	259.36 )	/ 2 )
	=	-28.076	/	268.4955
	=	-10.46 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2022) EBIT data.

Cardiovascular Systems (FRA:R7Y1) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cardiovascular Systems ROCE % Related Terms

Thank you for viewing the detailed overview of Cardiovascular Systems's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardiovascular Systems (FRA:R7Y1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cardiovascular Systems Inc (FRA:R7Y1) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1225 Old Highway 8 Northwest, Saint Paul, MN, USA, 55112-6416

Website

https://www.csi360.com

Cardiovascular Systems Inc is a medical technology company focused on patients with peripheral and coronary artery diseases. Its peripheral artery disease systems are catheter-based platforms used to treat plaque in leg arteries above and below the knee. The firm's orbital atherectomy systems are used in peripheral and coronary commercial applications. Its OAS products include the Diamondback 360 Peripheral and Stealth 360 systems. Sales of Peripheral OAS contribute the majority of revenue. Cardiovascular systems generate the vast majority of its revenue in the United States.

Cardiovascular Systems (FRA:R7Y1) Headlines

No Headlines